ResearcherUniversity of TriesteActive in the last 2 years
Davide Busato
Matched on ORCID iD 0000-0001-8127-3948; OpenAlex author ID A5016085898. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 2 papers
Papers 5
- The anti-GPC1 antibody AT101 as effective targeting agent for chemotherapeutic-loaded chitosan nanobubbles in the treatment of pancreatic adenocarcinoma. Co-author DOI 10.1016/j.biopha.2026.119956↗
- PLGA/PVA nanoparticles to deliver a protein-based cancer vaccine targeting GPC1 for the treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/17435889.2026.2676617↗
- Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer. Co-author DOI 10.3390/medicina61040633↗
- A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-023-04745-9↗
- The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ijms231810279↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Giuseppe Toffoli · 5 shared papers, 2022–2026 · strength 1.24
- Paper Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreat… DOI 10.3390/medicina61040633↗
- Paper PLGA/PVA nanoparticles to deliver a protein-based cancer vaccine targeting GPC1 for the treatment of pancreatic ductal … DOI 10.1080/17435889.2026.2676617↗
- Paper The anti-GPC1 antibody AT101 as effective targeting agent for chemotherapeutic-loaded chitosan nanobubbles in the treat… DOI 10.1016/j.biopha.2026.119956↗
- Michele Dal Bo · 4 shared papers, 2022–2026 · strength 0.93
- Paper PLGA/PVA nanoparticles to deliver a protein-based cancer vaccine targeting GPC1 for the treatment of pancreatic ductal … DOI 10.1080/17435889.2026.2676617↗
- Paper The anti-GPC1 antibody AT101 as effective targeting agent for chemotherapeutic-loaded chitosan nanobubbles in the treat… DOI 10.1016/j.biopha.2026.119956↗
- Paper The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ducta… DOI 10.3390/ijms231810279↗
- Amin Safa · 2 shared papers, 2025–2026 · strength 0.60
- Paper Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreat… DOI 10.3390/medicina61040633↗
- Paper PLGA/PVA nanoparticles to deliver a protein-based cancer vaccine targeting GPC1 for the treatment of pancreatic ductal … DOI 10.1080/17435889.2026.2676617↗
- Idris Vruzhaj · 2 shared papers, 2025–2026 · strength 0.60
- Paper Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreat… DOI 10.3390/medicina61040633↗
- Paper PLGA/PVA nanoparticles to deliver a protein-based cancer vaccine targeting GPC1 for the treatment of pancreatic ductal … DOI 10.1080/17435889.2026.2676617↗
- Marta Gambirasi · 2 shared papers, 2025–2026 · strength 0.60
- Paper Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreat… DOI 10.3390/medicina61040633↗
- Paper PLGA/PVA nanoparticles to deliver a protein-based cancer vaccine targeting GPC1 for the treatment of pancreatic ductal … DOI 10.1080/17435889.2026.2676617↗
- Monica Argenziano · 1 shared paper, 2026 · strength 0.24
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.